Background.Treatment options of recurrent Baby Muslins malignant gliomas are very limited and with a poor survival benefit.The results from phase II trials suggest that the combination of bevacizumab and irinotecan is beneficial.
Patients and methods.The medical documentation of 19 adult patients with recurrent malignant gliomas was retrospectively reviewed.All patients received bevacizumab (10 mg/kg) and irinotecan (340 Screen Protector mg/m2 or 125 mg/m2) every two weeks.
Patient clinical characteristics, drug toxicities, response rate, progression free survival (PFS) and overall survival (OS) were evaluated.